Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP45ME)

• Drug Name: Lisocabtagene maraleucel Drug Info
• Synonyms: JCAR017

Indication

Disease Entry	ICD 11	Status	REF
Large B-cell lymphoma	2A81	Approved	[1]
Central nervous system lymphoma	2B33.5	Phase 2	[2]
Follicular lymphoma	2A80	Phase 2	[2]
Non-hodgkin lymphoma	2B33.5	Phase 2	[3]
Richter syndrome	2A81.Y	Phase 2	[2]
Precursor B-lymphoblastic neoplasm	2A70	Phase 1/2	[4]

• Cross-matching ID: TTD Drug ID: DMP45ME

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[6]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[7]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[8]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[9]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[10]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[11]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[12]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[13]
CD19 CAR T cells	DM32148	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [2] ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
• [3] ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
• [4] ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
• [5] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [10] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [11] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [12] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [13] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [14] ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma